Literature DB >> 15694084

Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia.

M Shaarawy1, F Al-Sokkary, M Sheba, O Wahba, H O Kandil, I Abdel-Mohsen.   

Abstract

OBJECTIVE: To investigate the role of the angiogenic factors, vascular endothelial growth factor (VEGF) and angiogenin in the pathophysiology of preeclampsia and how their concentrations correlate with the severity of the disease and fetal outcome. PATIENTS AND METHODS: A prospective study was carried out on 71 pregnant patients with preeclampsia and 20 pregnant normotensive controls. Maternal serum levels of VEGF and angiogenin were determined in all cases by enzyme immunoassay. Assessment of fetal well-being using the Biophysical Profile Score (BPS), umbilical and uterine artery Doppler velocimetry, and infant birthweight were carried out.
RESULTS: Maternal serum VEGF and angiogenin levels were significantly increased in cases of mild and severe preeclampsia compared to controls. Their increase was positively correlated with elevated systolic and diastolic blood pressure, as well as poor BPS, abnormal Doppler velocimetry, and low birthweight.
CONCLUSION: Elevated levels of both VEGF and angiogenin could confirm the existence of vascular reactivity and endothelial disturbance in preeclampsia. Measurement of these angiogenic factors in maternal serum may be a useful as biomarkers for the assessment of the severity of the disease and of fetal outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15694084     DOI: 10.1016/j.ijgo.2004.10.005

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  9 in total

1.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

Review 2.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

3.  Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy.

Authors:  Alain F Tanbe; Raouf A Khalil
Journal:  Curr Bioact Compd       Date:  2010-03-01

Review 4.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

Review 5.  Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Stephanie J Sheppard; Raouf A Khalil
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-03

6.  Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women.

Authors:  Sarah N Cross; Elena Ratner; Thomas J Rutherford; Peter E Schwartz; Errol R Norwitz
Journal:  Rev Obstet Gynecol       Date:  2012

Review 7.  The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.

Authors:  Dongdong Yu; Yikai Cai; Wei Zhou; Jinghao Sheng; Zhengping Xu
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

Review 8.  Unravelling the potential of angiogenic factors for the early prediction of preeclampsia.

Authors:  Juilee S Deshpande; Deepali P Sundrani; Akriti S Sahay; Sanjay A Gupte; Sadhana R Joshi
Journal:  Hypertens Res       Date:  2021-04-01       Impact factor: 3.872

9.  Association Between Endothelial Nitric Oxide Synthase (eNOS) -786 T/C and 27-bp VNTR 4b/a Polymorphisms and Preeclampsia Development.

Authors:  Tamara Sljivancanin Jakovljevic; Olivera Kontic-Vucinic; Nadja Nikolic; Jelena Carkic; Jelena Stamenkovic; Ivan Soldatovic; Jelena Milasin
Journal:  Reprod Sci       Date:  2021-05-27       Impact factor: 3.060

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.